ARE N-of-1 trials an economically viable option to improve access to selected high cost medications? The Australian experience

Paul A. Scuffham, Michael J. Yelland*, Jane Nikles, Eva Pietrzak, David Wilkinson

*Corresponding author for this work

Research output: Contribution to journalArticlepeer-review

15 Citations (Scopus)

Fingerprint Dive into the research topics of 'ARE N-of-1 trials an economically viable option to improve access to selected high cost medications? The Australian experience'. Together they form a unique fingerprint.

Medicine & Life Sciences